Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide

Launched by SHEBA MEDICAL CENTER · Jul 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a special program that combines exercise and nutrition to help older adults with Type 2 diabetes and obesity maintain their muscle strength and physical function while they are being treated with a medication called Semaglutide. The researchers want to find out if this program can slow down the loss of muscle mass and strength in people aged 65 to 75 who have these conditions.

To participate, individuals need to be between 65 and 75 years old, have been diagnosed with Type 2 diabetes, and have a body mass index (BMI) of 27 or higher, indicating they are overweight or obese. Participants will take Semaglutide once a week for six months and will visit the clinic every two months for check-ups. They will also keep a diary of their exercise and food intake. Those in the exercise and nutrition program will join online workouts and receive personal advice on healthy eating. It's important to note that there are certain health conditions that may prevent someone from participating, so it's best to check with a healthcare provider if you're interested.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients 65-75 years old.
• • 2. Patients who were previously diagnosed with type 2 diabetes.
• • 3. Overweight / obesity (body mass index, BMI ≥ 27 kg/m2).
• Exclusion Criteria:
• • 1. Patients with significant hearing or visual disability.
• • 2. Patients with Estimated Glomerular Filtration Rate (eGFR)\<30 ml/min/1.73 m2.
• • 3. Patients who are in active nutritional therapy.
• • 4. Patients who changed their diet recently (\< 1 month) and/or in a weight-loss program with \>5% weight loss or used anti-obesity drugs in the last 3 months.
• • 5. Patients who reported a weight loss of \>5kg within 90 days of screening
• • 6. Patients who were on Glucagon-like peptide-1 receptor agonists (GLP-1-RA) treatment during the last 3 months.
• • 7. Patients with musculoskeletal disorders, which, by the judgment of the investigators, would limit their ability to perform the exercise training.
• • 8. Patients with neurological diseases, which by the judgment of the investigators, would affect their ability to participate in the trial.
• • 9. Patients with a history of amputation that impairs their ability to participate in the exercise program.
• • 10. Patients with disabilities, which, by the judgment of the investigators, would affect their ability to participate in the trial.
• • 11. Patients who use a walking aid.
• • 12. Patients who are currently using systemic steroids.
• • 13. Patients with active oncological diseases, excluding non-melanoma skin cancer.
• • 14. Patients with diagnosed dementia or cognitive impairment that, in the view of the researchers, may impair their ability to sign a consent form or participate in the trial.
• • 15. Patients who were hospitalized in the past month.
• • 16. Patients who exercise regularly and in the eyes of the examiner will not benefit from the intervention program.
• • 17. Anyone who is not suitable to participate in the study, according to the researcher's discretion.
• • 18. Any contraindication to Magnetic resonance imaging (MRI) (e.g., MRI non-compatible cardiac implantable electronic device, metallic foreign bodies, implantable neurostimulation system, cochlear implants/ear implant, non-removable drug infusion pumps, catheters with metallic components, cerebral artery aneurysm clips which), or inability to perform an MRI scanner (e.g., claustrophobia).
• • 19. Patients who do not fit within the measurement field of view of the Dual-energy X-ray absorptiometry (DXA) scanner in a supine position with the arms next to the body.